



ENDO  AX <sup>®</sup>


The vascular health  
screening medical device

---

CHIARA  
CALAMANTI  
PhD

---


# DYING FROM CARDIOVASCULAR DISEASE (EU)




## CVD IS KILLER NUMBER ONE

**1.8 MILLION**  
CARDIOVASCULAR DISEASE DEATHS PER YEAR

**5000**  
CARDIOVASCULAR DISEASE DEATHS PER DAY



“ Endothelial Dysfunction: A Barometer of Cardiovascular Risk ”





IOT project start


Ethical Committee and Ministry of Health - **APPROVED**




**Start** with the clinical investigation Fabriano Hospital



- *New Clinical Trials in collaboration with International Institutions*  
- *Start new Projects!*




2016



2017

B



2018

C



2019

D



2020

E




2021

F



2022

G



2023

H

Strumedical 

R&D

Development of Endomax

Production of prototypes

**End** of clinical investigation and IOT project




# KEY FACTORS

- ✓ PATENT
- ✓ CLINICAL
- ✓ INVESTIGATION
- ✓ DEVICE TESTED
- ✓ READY FOR PRODUCTION
- ⌚ CE MARK in progress



HOME CARE



EXAM FOR EVERYONE


- STAND - ALONE
- NOT-INVASIVE
- OPERATOR-INDEPENDENT
- USER - FRIENDLY
- SMALL, LIGHTWEIGHT, PORTABLE
- AUTOMATIC MEASUREMENT

## STRENGTHS

- Ease to use (is not necessary a skilled operator) and stand alone
- Selling price vs competitors
- Few direct competitors
- Patent

## WEAKNESSES

- Lack of a protocol to launch the product into the National Health System
- Clinic tests for some pathologies are still work in progress



- Get subsidies from UE and the Italian Government
- Booming Market
- **New preventive care programs**
- **Pharmaceutical companies might be interested for drug therapy monitoring**


## OPPORTUNITIES

- Though the technique is simple yet the acceptance across globe is hampered due to variation in results
- Big players are becoming interested in this field

## THREATS

● ENDOMAX

● COMPETITORS



HIGH

MARKET SHARE

LOW

CONTENDERS

LEADERS

NICHE


HIGH PERFORMERS

HIGH

LOW

PRICE



# Production and Sales Revenue Forecasting - Endomax







ANTROPHOMETRIC DATA






DIAGNOSTIC DATA

## Patients Recruited

 PARTNERS!

**Jan, 2025**

**1<sup>st</sup> MULTICENTER CLINICAL TRIAL**

**12 months**

**Jan 2025- Jan 2026**

**2<sup>nd</sup> CLINICAL TRIAL in DIABETIC PATIENTS**

**6 months**

**July 2025- Dec 2025**




UNIVERSITÀ POLITECNICA DELLE MARCHE

**PATENT** ✓

**Draft Protocol Available**

**CET/CEN Consultation Initiated**

**Apply for EC approval**

**Apply for Health Ministry**

**Estimated CET/CEN Approval Date**

**Initiation 1<sup>st</sup> MULTICENTER CLINICAL TRIAL**

**2<sup>nd</sup> CLINICAL TRIAL in DIABETIC PATIENTS**

**PMCF**

**Oct 2025**



**TODAY**

**ISO 13485  
ISO 9001**

**CE MARK**

  
**PRODUCT LAUNCH**

 **INVESTORS!**



Do you want to act to save human lives?



We are working to save human lives.  
What about you?



Do you know Endothelial  
dysfunctions?



Is your Endothelium working well?

THANKS

Chiara Calamanti

[www.strumedical.com](http://www.strumedical.com)

[c.calamanti@strumedical.com](mailto:c.calamanti@strumedical.com)

[www.endomax.eu](http://www.endomax.eu)

ENDO  MAX